<DOC>
	<DOCNO>NCT00794560</DOCNO>
	<brief_summary>There little data available compliance self-injected low molecular weight heparin ( LMWH ) , , definitely show compliance represent significant problem . We therefore aim ) record drug use problem patient include compliance , b ) develop `` SOP '' first instruction pharmacist subsequent pharmaceutical care c ) compare intensive pharmaceutical care ( intervention ) vs. standard care ( control ) provide pharmacy patient prescription LMWH outpatient treatment . Hypothesis : Intensive pharmaceutical care ambulatory patient self-inject low molecular weight heparin result improve compliance , safety satisfaction well few complication .</brief_summary>
	<brief_title>Self-management Low Molecular Weight Heparin Therapy</brief_title>
	<detailed_description>Patient recruitment community pharmacy enable test feasibility intervention daily-practice condition facilitate recruitment large number patient . Data collection : - telephone interview structure questionnaire begin end therapy - monitor self-injection study center patient 's home ( direct observation technique [ DOT ] ) - compliance measurement : answer patient interview , compare number use syrinx vs. number prescribe syrinx ( analogue `` pill count '' ) , measure residual volume recycle syrinx - record fine motor skill adapt `` Disabilities Arm , Shoulder Hand '' questionnaire ( DASH questionnaire )</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Patients recruit orthopedic clinic , emergency department community pharmacy prescription LMWH outpatient treatment . selfapplication LMWH german / english speaking &gt; clinical setting : Dalteparin &gt; daily life setting : LMWH ( readytouse syrinx ) control group : selfapplication application another person ( family member , medical person , etc . ) patient 's home far away study center</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Heparin , Low-Molecular-Weight</keyword>
	<keyword>compliance</keyword>
	<keyword>drug safety</keyword>
	<keyword>self-administration</keyword>
	<keyword>ambulatory Care</keyword>
	<keyword>Pharmaceutical Services</keyword>
</DOC>